drugset
drugset / Trial / NCT06303570

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

NCT06303570 ↗

Phase 2 Active not recruiting 19 enrolled Caliway Biopharmaceuticals Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.

Timeline

Start
2024-11-27
Primary completion
2026-03-23
Completion
2026-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CBL-514 Unknown 5 mg —
Subject CBL-514 Unknown 15 mg —
Subject CBL-514 Unknown 25 mg —
Subject CBL-514 Unknown 40 mg —
Subject CBL-514 Unknown 60 mg —

Indications

adiposis dolorosa